FDA warned Thermoteknix that its FevIR Scan 2 COVID-19 temperature-screening device was adulterated and misbranded and sold in the U.S. without FDA authorization.
What happened
FDA reviewed Thermoteknix's website on February 22, 2021, and its Twitter, Vimeo, and Facebook pages, which directed consumers to the website. FDA found the website offered the FevIR Scan 2 for sale in the United States with statements that it helps fight the spread of COVID-19 and provides temperature screening and face mask detection. FDA said the product was offered without marketing approval, clearance, or authorization.
What FDA found
The FevIR Scan 2 is a device intended to diagnose or prevent COVID-19 because the company's website and social media said it helps fight the spread of coronavirus.
section 201(h) of the Act, 21 U.S.C. § 321(h)The company offered the device for sale in the United States without FDA marketing approval, clearance, or authorization.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The company did not have an approved premarket approval application or an approved investigational device exemption for the product.
section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)FDA said the product was misbranded because the company did not notify FDA of its intent to introduce the product into interstate commerce for commercial distribution as required by 510(k).
section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)FDA said introduction or delivery for introduction of the product into interstate commerce is prohibited.
section 301(a), 21 U.S.C. § 331(a)
What FDA wants
FDA asked the company to take immediate action to stop selling the product for COVID-19 and to email FDA within 48 hours describing steps taken to address the violations and prevent recurrence, or explain any delay.
Who should pay attention
- U.S. businesses using temperature-screening cameras
- medical device distributors and importers
- marketing teams making COVID-19 claims
This is a summary. Read the original letter on fda.gov.